Amarin stock heads toward highest prices in more than a decade after new Vascepa FDA approval

Amarin Corp.'s stock moved toward a new decade-high price in the extended session Friday after a Food and Drug Administration marketing approval that gave its drug Vascepa a wider use. U.S. traded shares of Dublin-based Amarin (AMRN) rose more than 5% Friday after being halted for half the trading day and into the after-hours session .